Talis conducted a comprehensive in silico assessment comparing the Omicron (B1.1.529) variant published sequences from the GISAID database to its Talis One COVID-19 Test System. The bioinformatics analysis concluded that the Talis One COVID-19 molecular nucleic acid amplification test (NAAT) continues to be able to identify positive cases of COVID-19 caused by Omicron.
Like all viruses, SARS-CoV-2 continues to mutate. In anticipation of this fact, our scientists developed a test with a dual-gene target to ensure accurate results even in the case where one of the targets may become impacted by a mutation. The Omicron variant has been found to show multiple mutations, with a majority occurring on the spike (S) protein. Talis’ molecular NAAT does not rely on the S gene to detect the virus but rather focuses on two other targets: the N and Orf1a/b genes. Individually, >99% of the published Omicron sequences as of December 1, 2021, are a perfect match to at least one of the Talis primer regions, while across both targets, 100% of the sequences match at least one of the primer sets.
The robust multiple target test design helps to ensure that clinicians, researchers and public health officials have an effective tool for COVID-19 testing-even as the genetic makeup of the virus evolves.
Talis will continue surveillance of emerging SARS-CoV-2 variants of concern/interest (VOC/I) by assessing reactivity against genome sequence databases.
To date, Talis has performed assessments looking at the following variants
- Alpha (B.1.1.7)
- Beta (B.1.351)
- Epsilon (B.1.427 and B.1.429)
- Eta (B.1.525)
- Iota (B.1.525)
- Gamma (P.1)
- Zeta (P.2)
- Omicron (B.1.1.529)
Join Our Newsletter
Subscribe to our newsletter for information about our products and company updates.
The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.
*Additional testing solutions are currently in development and not available for sale.
- Data on file with Talis Biomedical. GISAID Database accessed December 1, 2021.